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We used mutant yeast and human TBP molecules with an altered DNA-binding specificity to examine the 
role of TBP in transcriptional activation in vivo. We show that yeast TBP is functionally equivalent to human 
TBP for response to numerous transcriptional activators in human cells, including those that do not function 
in yeast. Despite the extensive conservation of TBP, its ability to respond to transcriptional activators in vivo 
is curiously resistant to clustered sets of alanine substitution mutations in different regions of the protein, 
including those that disrupt DNA binding and basal transcription in vitro. Combined sets of these mutations, 
however, can attenuate the in vivo activity of TBP and can differentially affect response to different activation 
domains. Although the activity of TBP mutants in vivo did not correlate with DNA binding or basal 
transcription in vitro, it did correlate with binding in vitro to the largest subunit of TFIID, hTAFnZSO. 
Together, these data suggest that TBP utilizes multiple interactions across its surface to respond to RNA 
polymerase II transcriptional activators in vivo; some of these interactions appear to involve recruitment of 
TBP into TFIID, whereas others are involved in response to specific types of transcriptional activators. 
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RNA polymerase II transcription in higher eukaryotes is 
regulated by a diverse range of sequence-specific tran­
scription factors, which act in combination to signal the 
transcriptional machinery to initiate transcription (for 
review, see McKnight and Yamamoto 1992). Although 
much emphasis has been placed on how activators stim­
ulate the basal machinery in vitro (for review, see Tjian 
and Maniatis 1994), little is known of the way in which 
the basal factors respond to activators in vivo. 
Transcriptional activators appear to work in vitro by 
stimulating the ordered assembly of general transcrip­
tion factors (GTFs) at a promoter, forming a preinitiation 
complex that can initiate transcription (for review, see 
Zawel and Reinberg 1993). For TATA box-containing, 
RNA polymerase Il-transcribed genes, formation of this 
complex begins with binding of the TATA box-binding 
protein (TBP) and its associated factors (TAFs) to the 
TATA box, followed by the sequential addition of other 
GTFs including RNA polymerase 11 (for review, see Bu-
ratowski 1994). By targeting one or more of the general 
factors and facilitating their entry onto the promoter, 
activators can significantly enhance the rate of in vitro 
preinitiation complex assembly (Lieberman and Berk 
1991, 1994; Lin and Green 1991; Choy and Green 1993). 
The process of activation in vivo, however, may be 
different. For example, the response of the fractionated 
GTFs to activators during preinitiation complex assem­
bly in vitro may not fully reflect the in vivo situation, 
because the GTFs may exist in large multicomponent 
complexes (Thompson et al. 1993; Kim et al. 1994; 
Koleske and Young 1994); the mechanisms that activate 
such complexes may differ from those that affect the 
isolated GTFs in vitro. In addition, although most in 
vitro studies examine single rounds of transcription ini­
tiation, the processes of activated reinitiation are likely 
to be more important for activator function in vivo, as 
activators can sustain high levels of transcription from 
the one or two functional gene copies within a cell. 
Of the general transcription factors, TBP is studied 
most extensively (for review, see Hernandez 1993). It is a 
highly conserved protein, containing a 180-amino-acid 
carboxy-terminal domain of known structure (Niklov et 
al. 1992; J.L. Kim et al. 1993; Y. Kim et al. 1993) that 
shares >80% sequence identity between yeast and hu­
mans. TBP plays an important role in transcriptional ac­
tivation in vitro, both as a direct target for activators 
(Ingles et al. 1991; Lieberman and Berk 1991; Truant et 
al. 1993; Emili et al. 1994) and by its association with 
other target proteins, including TFIIB (Lin and Green 
1991) and the TAFs (for review, see Goodrich and Tjian 
1994). The association of TBP with TAFs (forming the 
TFIID complex) is particularly important to the process 
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of activation, as the TAFs are essential for activated tran­
scription but dispensable for basal transcription in vitro 
(Dynlacht et al. 1991; Tanese et al. 1991; Zhou et al. 
1993) and bridge activators to other components of the 
transcriptional machinery (for review, see Tjian and Ma-
niatis 1994; Chen et al. 1994). 
Previous studies of TBP in vivo have focused on the 
isolation of temperature-sensitive mutants in yeast. 
These studies have provided genetic evidence that TBP is 
involved in transcription by all three classes of RNA 
polymerase (Cormack and Struhl 1992; Schultz et al. 
1992) and have identified a surface of TBP, spanning the 
two largest a-helices, that is required for RNA polymer­
ase III transcription (Cormack and Struhl 1993). Such 
analyses are limited, however, to the isolation of mu­
tants that generate a conditional growth phenotype, and 
to date no TBP mutants specifically defective for acti­
vated RNA polymerase II transcription have been iden­
tified by this approach. In addition, as some activation 
domains, such as those from the human transcription 
factor Spl, do not display activity in yeast (Emili et al. 
1994; Kunzler et al. 1994), an analysis in human cells can 
better probe how a wide variety of nonconserved activa­
tors act on the relatively conserved basal transcriptional 
machinery. 
In this paper we investigate the role played by TBP in 
activated RNA polymerase II transcription in human 
cells. We show that this activity of TBP in vivo involves 
numerous interactions across the surface of the mole­
cule and that different regions of TBP participate in re­
sponse to different transcriptional activators. Much of 
the behavior of TBP in vivo appears to reflect the nature 
of the association between TBP and the largest subunit 
of TFIID, hTAFn250. These data underscore the impor­
tance of TBP-TAF interactions for activated transcrip­
tion but also reveal that TBP functions in other ways to 
respond to transcriptional activators in vivo. 
Results 
Experimental design 
The structure of the conserved carboxy-terminal domain 
of TBP is represented in Figure 1. The underside of the 
saddle-like structure (shown in Fig. IB) contains eight 
antiparallel p-sheets (Niklov et al. 1992) that form the 
DNA-binding surface of TBP (J.L. Kim et al. 1993; Y. Kim 
et al. 1993). Accordingly, when TBP is bound to the 
DNA, much of the opposite surface of the molecule, in­
cluding the four a-helices and many of the loops con­
necting the p-strands, should be available for interaction 
with other proteins. 
To monitor the activity of TBP in human cells, we 
used the altered-specificity TBP assay first described by 
Strubin and Struhl (1992). This assay employs a TBP de­
rivative with a triple amino acid substitution on its 
DNA-binding surface (indicated in orange in Fig. 1). This 
TBP derivative (TBP^g) has a relaxed DNA-binding spec­
ificity and recognizes both a canonical TAT AAA box and 
an altered TGTAAA box (Strubin and Struhl 1992). The 
combination of TEP^s and the TGTAAA box circum­
vents the activity of endogenous wild-type TBP in yeast 
(Strubin and Struhl 1992), plant (Heard et al. 1993), and 
mammalian (Keaveney et al. 1993) cells and thus allows 
the effects of in vitro manipulations in TBP to be exam­
ined in vivo. 
We introduced various mutations into TBP^g and an­
alyzed the in vivo effects of these mutations on response 
to a battery of different transcriptional activation do­
mains, each fused to the heterologous yeast GAL4 DNA-
binding domain (residues 1-94; Carey et al. 1989). The 
structure of these GAL4—fusion activators is represented 
in Figure 2A. Spl*^ contains two copies of the glutamine-
rich Spl B domain (Courey and Tjian 1988) and was cho­
sen because it activates transcription in human but not 
yeast cells (Kunzler et al. 1994). Oct-2^ and Oct-2^ are 
both derived from the human transcription factor Oct-2 
but have distinctly different amino acid compositions: 
Oct-2^ consists of four copies of an 18-amino-acid glu-
tamine-rich segment from the amino-terminal activa­
tion domain of Oct-2 (Tanaka and Herr 1994), whereas 
Oct-2^ carries two copies of a 42-amino-acid proline-rich 
activation domain from the carboxyl terminus of Oct-2 
(Tanaka et al. 1994). CTF^ and VP16 both carry single-
copy activation domains from CTF (Mermod et al. 1989) 
and the herpes simplex virus tians-sictivsitor VP16 
(Triezenberg et al. 1988), respectively. 
Figure 2A also lists the relative activity of the various 
GAL4—fusion activators on the wild-type counterpart of 
the TGTAAA-containing c-/os reporter used in these 
studies (see below). Because the VP16 activation domain 
was much more active than the other activation do­
mains examined, the amino- (VP16N) and carboxy-
(VP16c) terminal halves of this domain (Regier et al. 
1993) were also assayed individually. These truncated 
VPI6 activation domains displayed activities similar to 
those of the other activators (see Fig. 2A). 
Figure 2B shows the structure of the wild-type and 
TGTAAA-containing c-/os reporters. The wild-type 
TAT AAA reporter construct contains the c-/os promoter 
to position - 5 6 (Berkowitz et al. 1989) linked to four 
upstream synthetic GAL4 DNA-binding sites. The 
TGTAAA reporter is identical, except for the single 
A ^  G transition in the TATAAA box (TATAAA to TG­
TAAA). As shown below, this mutation in the c-/os pro­
moter disrupts activation in the presence of wild-type 
TBP but not TBPAS- The disruption of wild-type TBP 
activity by the TGTAAA mutation was promoter spe­
cific; a corresponding mutation in the p-globin promoter 
did not attenuate in vivo transcriptional activity (data 
not shown). 
TBP and GAL4-fusion activator molecules were tran­
siently coexpressed with the c-/os reporter constructs in 
human HeLa cells. Correctly initiated transcripts from 
the c-fos reporters and from an a-globin internal control 
plasmid were quantitated by RNase protection analysis. 
The a-globin signals were used to normalize for differ­
ences in transfection efficiency and were not detectably 
affected by transient expression of exogenous TBP at the 
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Figure 1. Ribbon diagram of TBP structure, showing the positions of the systematic sets of mutations generated for in vivo analysis. 
(A) Top view; (B) front view. Depicted is the solved crystal structure for Arabidopsis thaliana TBP-2 (Niklov et al. 1992); the yeast TBP 
structure is similar (Y. Kim et al. 1993) and is likely to be the conformation adopted by human TBP in this region. The a-carbon 
backbone is shown in white, and the position of the three altered-specificity (AS) substitutions (Strubin and Struhl 1992) are shown 
in orange. (Red) Position of the alanine substitution mutations HI and HI'; (green) position of the H2 and H2' mutations; (purple) 
position of the mutations on the two loops connecting strands S3/S4 and S3'/S4'. These mutations are described in detail in Table 1. 
levels used in these experiments (data not shown). Ex­
pression of the mutant TBP^s molecules was monitored 
by quantitative Western blot analysis of protein extracts 
from transfected cells (data not shown), hi all experi­
ments the amount of TEP^s expression construct used 
was adjusted to give equivalent levels of expression for 
each TBP AS. 
Figure 3 shows the response of wild-type and mutant 
TBPAS molecules to each of the GAL4-fusion activators. 
Because the different activators possess very different 
relative activities (see Fig. 2A), different length expo­
sures are shown for each activator. The wild-type 
TATAAA c-fos promoter responded well to the different 
activation domains examined (Fig 3, cf. lanes 1 and 2, 
panels A-G; see also Fig. 2A). Introduction of the TG-
TAAA mutation in the c-/os promoter significantly at­
tenuated the transcriptional response (cf. lanes 2 and 4), 
from between 12-fold for VP16 (E) to 17-fold for Oct-2Q 
(B). Transient coexpression of full-length human TBP AS 
(lane 6), but not an equivalent amount of wild-type hu­
man TBP (lane 5), restored transcriptional activation (cf. 
lanes 2 and 6, A-G). Activation by TEP^s (lane 6) was 
still dependent on expression of the GAL4 activator (data 
not shown). The difference in c-/os promoter activity ob­
served in the absence (lane 4) and the presence (lane 6) 
of TBPAS provides the assay for wild-type and mutant 
TBPAS function in response to each of the activators. 
The activity of TBP^s was not dependent on the non-
conserved amino-terminal region of human TBP (resi­
dues 2-159), as its deletion (AN; cf. lanes 6 and 7, A-G) 
did not diminish response to any of the GAL4-fusion 
activators examined—indeed, the Oct-2^ and V P 1 6 N ac­
tivators were three- to fivefold more active with the 
amino-terminally truncated TBP (cf. lanes 6 and 7, C and 
F). These data show that the nonconserved region of TBP 
is dispensable for RNA polymerase II transcriptional ac­
tivation in human cells as it is in vitro (Kelleher et al. 
1992; Zhou et al. 1993) and in yeast cells (Cormack et al. 
1991) and enabled us to confine our further mutational 
analysis to the conserved carboxy-terminal region of the 
protein. 
Human and yeast TBP support equivalent levels 
of transcriptional activation in human cells 
The carboxy-terminal 180 amino acids of human and 
yeast [Saccharomyces cerevisiae] TBP are 81% identical 
and are interchangeable for basal transcription and re­
sponse to acidic activators in vitro (Kelleher et al. 1992) 
and in vivo (Strubin and Struhl 1992; Keaveney et al. 
1993). Despite this high degree of sequence conservation, 
yeast TBP cannot replace human TBP for response to an 
"El A-like" activity in mouse embryonic carcinoma (EC) 
cells (Keaveney et al. 1993) and does not respond to Spl 
activation domains in yeast (Emili et al. 1994; Kiinzler et 
al. 1994). To investigate functional differences between 
human and yeast TBP, we therefore assayed the ability of 
yeast TBP to respond to our panel of activation domains 
in human cells. 
As shown in Figure 3, yeast and human TBP^s re­
sponded similarly to all of the GAL4-fusion activators 
examined (cf. lanes 6 and 14, A-G). Thus, yeast TBP can 
respond to a wide array of mammalian activation do­
mains in human cells. In particular, there was no signif­
icant difference in human and yeast TBP AS response to 
Spl*-^  (A), demonstrating that although the activation do­
mains of Spl do not activate transcription in yeast, yeast 
TBP can support activation by Spl in human cells. This 
result suggests that the role TBP plays in activated tran­
scription has been conserved between yeast and humans 
but that the accessory factors required for Spl activation 
are not conserved between these species. 
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GAL4-Activator 
Activation 
Domain 
Sp1(2xB) 
Oct-2(4xQ|||18) 
Oct-2(2xP42) 
CTF 
VP16(413-490) 
VP16(413-456) 
VP16(452-490) 
none 
Activation 
Domain 
Clnaracter 
Q-rich 
Q-rich 
P-rich 
P-rich 
Acidic 
Acidic 
Acidic 
none 
Relative 
Activity 
1.0 
3.3 
4.7 
5.1 
97 
7.8 
16 
0.04 
GAL4 DBD[1-94] 
B 
Promoter 
GAL4 Sites 
TATMA ^ D D O TATAAA 
r w \ > 
TGTAAA - D O X } - TGTAAA 
f W V > 
Figure 2. Activators and reporter con­
structs. [A] GAL4—fusion activators. Activa­
tion domains are classified as either glu-
tamine-rich (Q-rich), proline-rich (P-rich), or 
acidic and were expressed as fusions w i^th 
the yeast GAL4 DNA-binding domain 
(GAL4 DBD; residues 1-94). Spl^ was con­
structed by duplicating the B domain of Spl 
(Courey and Tjian 1988). The other activa­
tion domains have been described [4xQiiji8 
(Tanaka and Herr 1994); 2xP*^ (Tanaka et al. 
1994); CTF (Mermod et al. 1989); VP16N 
(413-456), VP16c(452-490), and VP16(413-
490) (Triezenberg et al. 1988; Regier et al. 
1993)]. (A) GAL4 DNA-binding domain 
alone. Relative activity refers to the maxi­
mal level of activation of the wild-type 
(TATAAA) c-/os reporter by each of the 
GAL4-fusion activators, setting the level of 
activation by the weakest activator, Spl* ,^ 
to 1.0. [B] The wild-type (TATAAA) and al­
tered (TGTAAA) c-/os reporter constructs. 
Both reporters contained the c-fos (-56) 
promoter (Berkowitz et al. 1989) down­
stream of four synthetic GAL4 DNA-bind­
ing sites (Tanaka et al. 1994). 
TBP activity in vivo is not greatly affected 
by clustered point mutations 
To examine the regions of TBP that are involved in re­
sponse to different activation domains in vivo, we con­
structed 10 amino acid substitution mutants as de­
scribed in Table 1. Tw^o sets of mutant TBPs were gen­
erated. The first set, IIA and pol III, was based on 
temperature-sensitive mutations that had been de­
scribed for yeast TBP (Buratowski and Zhou 1992; 
Schultz et al. 1992) and were introduced at correspond­
ing positions in both yeast and human TBP^s- The IIA 
mutation is a double lysine to leucine substitution on 
the surface of helix 2 that disrupts interaction of yeast 
TBP with human TFIIA in vitro (Buratowski and Zhou 
1992); it is not known whether this double leucine sub­
stitution in human TBP affects association with human 
TFIIA in vitro. The pol III mutation changes a conserved 
proline near the amino terminus of the TBP core to 
serine and disrupts transcription by RNA polymerase III 
but not RNA polymerase II (Schultz et al. 1992; S. Hahn, 
pers. comm.). 
The second set of mutations consisted of a series of 
systematic alanine substitutions on the solvent-exposed 
surface of DNA-bound human TBP, targeting the four 
a-helices {HI, HI', H2, and H2'] and two prominent 
loops connecting strands S3 and S4 [S3/S4] and S3' and 
S4' {S3'/S4']. Figure 1 shows the position of these muta­
tions on the TBP structure. In an attempt to disrupt hu­
man TBP activity, for each mutation we made double 
and, in one case {H2], triple alanine substitutions and 
focused on residues whose charge is conserved in TBPs 
from many species. Mutations at corresponding posi­
tions were made in each symmetrical half of the mole­
cule except in helices H2 and HI', where the position of 
charged residues is not strictly conserved between each 
repeat. Curiously, two of these TBP^s mutants, HI and 
H2' as well as the yeast pol III mutant could not be 
expressed in HeLa cells (Table 1). The reason for this lack 
of expression is not known, but a similar phenomenon 
has been described for other TBP mutants in yeast 
(Reddy and Hahn 1991) and may reflect incorrect protein 
folding (Parsell and Sauer 1989). 
The ability of the mutant TBPs to support activation 
by the GAL4—fusion activators is shown in Figure 3 
(lanes 8-13,15). The most notable feature of this analysis 
is that none of the mutations had a greater than threefold 
effect on the activity of TBP in vivo. In the context of 
yeast TBP^s/ the IIA mutation reduced response to all 
activators approximately twofold (cf. lanes 14 and 15, 
A—G). When the corresponding mutation was placed in 
the context of human TBP^s/ it modestly impaired acti-
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c-fos Promoter: 
TBP: 
[GAL4hACTIVAT0R: 
TATAAA 
1 II 
- + -
1 
+ + + 
TGTAAA 
human TBPAS 
^ -S ^ -j^ •?< ^ * Q. -JT JT 
+ + + + + + + 
1 
yeast 
TBPAS 
1 1 
+ + 
SpiQ M 
Figure 3. Effects of single regional mutations on 
TBP activity in human cells. RNase protection 
analysis of RNA isolated from HeLa cells tran­
siently transfected with the c-/os TATAAA (lanes 
1,2] or TGTAAA (lanes ^15] reporters, an appro­
priate TBP-expression construct (lanes 5-15], and 
an expression construct for each GAL4-fusion ac­
tivator, as indicated, (h) Wild-type human TBP. 
All other TBPs carried the altered-specificity sub­
stitutions and are described in Table 1. Only the 
correctly initiated c-/os transcripts, normalized to 
the a-globin signal, are shown. Transient expres­
sion of TBPAS i^ i the absence of a GAL4-fusion 
activator did not detectably increase transcription 
from the c-/os TGTAAA reporter or affect the 
a-globin signal (data not shown). As these GAL4-
fusion proteins activate transcription to different 
overall levels (Fig, 2A), exposure time for each au-
toradiograph is different. 
Oct-2Q 
Oct-2P 
C T F P 
VP16 
VP16N 
^^ll|i |i |l^lillli^^ |MI«H» ^ 
^^p f^pp 
VP16c ( § 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
vation only by the VP16-derived activators (cf. lanes 6 
and 8, E-G) and not the other activation domains exam­
ined (A-D). Therefore, despite the defect in interaction 
with human TFIIA in vitro, the yeast IIA mutant—and 
its human counterpart—can still respond to RNA poly­
merase II transcriptional activators in vivo. Similarly, 
the pol III mutat ion (lane 9) had only a small effect on 
transcriptional activation, again predominantly by the 
VP16-derived activators. This result is consistent with 
the ability of the pol III mutant TBP to support tran­
scription by RNA polymerase 11 in yeast (S. Hahn, pers. 
comm.). 
Curiously, the transcriptional effects of the systematic 
set of multiple alanine substitution mutations were also 
small and mainly confined to activation by the VP16-
derived activation domains (Fig. 3, cf. lane 6 with lanes 
10-13). The only reproducible effect was observed with 
the H2 mutant TBPAS, which was reduced two- to three­
fold in response to VP16. Comparison of full-length 
VP16 (lane 11, E) with its two less active subdomains 
(Fig. 3, F,G; see Fig. 2A) shows that the small selective 
effects of these mutations on VP16 activation do not 
simply result from its significantly greater transcrip­
tional activity, because V P I S N , which displays an activ­
ity similar to that of CTF^, mirrored the response of 
full-length VP16 and not CTF^ to each of the TBP mu­
tations (cf. lanes 10-13, D-F). 
The resistance of TBP activity in vivo to the effects of 
the multiple alanine substitutions was unexpected, 
given the high degree of sequence conservation in TBP 
across many species. It suggests that either these muta­
tions are not in regions of the protein that are involved in 
supporting activated transcription in vivo or that impor­
tant regions of TBP were being targeted, but the muta­
tions are not themselves sufficient to debilitate TBP ac­
tivity. 
Mutations in TBP that do not affect activity in vivo 
have large effects in vitro 
In a parallel series of experiments, we examined the po­
tential of the systematic set of multiple alanine substi­
tution mutants to bind DNA and to support basal tran­
scription in vitro. We analyzed the HI', H2, S3/S4, and 
S3'/S4' mutants because they are expressed in HeLa 
cells, allowing a comparison of in vitro and in vivo ac­
tivities. 
Full-length HI', H2', S3/S4, and S3'/S4' TBP^s mole­
cules were expressed in Escherichia coli and purified as 
fusions with glutathione S-transferase (GST) sequences. 
The DNA-binding capability of these GST-TBP^s mu­
tants was then examined by DNase I footprinting anal­
ysis, as shown in Figure 4. Titration of wild-type TBP^s 
on the TGTAAA c-fos promoter produced two clear re­
gions of protection (cf. lane 2 with lanes 3—5): a region 
encompassing 6 bases 5' and 4 bases 3 ' of the TGTAAA 
sequence and a region containing an A/T-rich vector 
sequence upstream of the GAL4 DNA-binding sites. In 
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Table 1. Alteied-specificity TBP molecules used in 
this study 
Name 
Color HeLa cell 
Species Mutation^ (Fig. 1) expression 
yTBPj^s .WT 
.IIA^ 
.pol Iir 
hTBPAs .WT 
AN 
.IIA 
.pol III 
.HI 
.HI' 
.H2 
.H2' 
.83/S4 
.S3'/S4' 
yeast 
yeast 
yeast 
human 
human 
human 
human 
human 
human 
human 
human 
human 
human 
none 
K(133)L 
K(138)L 
P(65)S 
none 
A2-159 
R(231)L 
K(236)L 
P(163)S 
D(179)A 
K(181)A 
R(269)A 
E(271)A 
R(231)A 
R(235)A 
R(239)A 
E(323)A 
E(326iA 
E(206)A 
R(208)A 
K(297)A 
Ri299)A 
red 
red 
green 
green 
purple 
purple 
^All TBPs carry the triple amino acid altered-specificity substi­
tutions, indicated in orange in Fig. 1. The coordinates for these 
substitutions are hTBPAs—I(292)F, V(301)T, L(303)V; yTBPAs— 
I(194)F, V(203)T, L(205)V. Coordinates are given for full-length 
human and yeast TBP, v^here appropriate. 
^(Buratowski and Zhou 1991). 
ISchultz et al. 1992). 
contrast, titration of identical amounts of the mutant 
TBPs produced patterns of DNase I protection that dif­
fered from wild-type TEP^g. Binding of the HI' and 
S3/S4 mutants, although detectable, was reduced ~ 10-
fold (cf. lanes 3-5 with lanes 6-8 and 12-13), whereas the 
S3'/S4' mutant TEP^s did not bind DNA to any signif­
icant degree (cf. lanes 3-5 with lanes 15-17). By compar­
ison, the H2 mutant bound DNA at levels similar to 
wild-type TBP^s (cf. lanes 3-5 with lanes 9-11); the 
binding of this mutant TBP^s, however, produced a 
imique DNase I hypersensitive site 3 bases 5' to the pro­
tected region (see arrow), possibly reflecting a different 
conformation of the TBP-DNA complex. As the HI', 
H2, S3/S4, and S3'/S4' TBP^s molecules can support 
activated transcription in vivo, these in vitro-binding 
data indicate that the ability of TBP to bind DNA in vitro 
does not necessarily correlate with its ability to function 
for activated transcription in vivo. Similar discrepancies 
between the DNA-binding potential of TBP and its abil­
ity to support transcription in vitro and in yeast cells 
have been reported (Cormack and Struhl 1992,- Lee et al. 
1992; Schultz et al. 1992; Yamamoto et al. 1992). 
Figure 5 shows the effects of the four sets of systematic 
alanine substitutions on the capacity of TBP^s to sup­
port basal transcription from the TGTAAA c-/os reporter 
in vitro. The results of RNase protection analysis per­
formed on RNA transcribed in crude HeLa cell nuclear 
extract reveal that in the absence of added wild-type 
GST-TBP^s/ no basal transcription was observed from 
this promoter (lane 1). Addition of wild-type GST-TEP^s 
resulted in a high level of correctly initiated transcripts 
(lane 2), whereas the two mutant TBP^^g molecules 
HI' and S3/S4, which bound DNA poorly, supported 
nearly wild-type levels of basal transcription (cf. lane 2 
with lanes 3 and 5). In contrast, mutants H2 (lane 4) and 
S3'IS4' (lane 6) showed no detectable basal activity in 
this assay, even though the H2 mutant binds well to 
DNA (Fig. 4). Taken together with the in vivo fimctional 
data (Fig. 3), this result demonstrates that the ability of 
GST4ITBPAS; WT HV S3/S4 S3'/S4' 
m ii.i WW 'i?? 
S mmSt III 'lis 
m m-m-^ ### #•■•• 
Iff lii^m 
IB : !-•" 38 5* * SJ ^ 
W^f§ 
3 4 5 6 7 9 10 11 12 13 14 15 16 17 
Figure 4. Alanine substitution mutations on the surface of hu­
man TBP affect DNA binding in vitro. For DNase I footprinting 
analysis, increasing amounts of recombinant GST-hTSP^^s fu­
sion proteins were incubated with an end-labeled DNA frag­
ment spanning the altered c-/os TGTAAA box, the four syn­
thetic GAL4 DNA-binding sites, and an A/T-rich vector se­
quence, as indicated. Each titration represents a 10-fold range in 
the amount of full-length GST-hTBPAs added, from 15-150 ng. 
The region of protection spanning the TGTAAA box is brack­
eted, and the position of the hypersensitive site induced by the 
H2 mutant TBP is indicated by an arrow. (G-l-A) Chemical se­
quencing reactions on the same labeled probe. 
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TBP to support basal transcription in vitro is not a pre­
requisite for its ability to support activated transcription 
in vivo. Moreover, this result, together with the DNA-
binding studies described above, suggests that interac­
tion of TBP with cellular components in vivo can coun­
teract the effects of mutations in TBP that disrupt DNA 
binding {HI', S3/S4, and S3'/S4') or basal transcription 
(H2 and 537S4') in vitro. 
Combined sets of mutations in different regions 
of TBP disrupt transcriptional activation in vivo 
As the activity of TBP in vivo was relatively unaffected 
by mutations in single regions of the protein, we rea­
soned that the functioning of TBP may depend on mul­
tiple, redundant interactions at different points across its 
surface. One prediction of this hypothesis is that com­
bined mutations in different regions of TBP may have a 
significant effect on its activity in vivo. To explore this 
possibility, we made all combinations of the HI', H2, 
S3/S4, and S3'/S4' mutations and assayed the ability of 
the combined mutant TBP^s molecules to respond to the 
different activation domains in vivo. 
Figure 6 shows the response of Oct-l'^, CTF^, full-
length VP16, and V P 1 6 N to each of the combined sets of 
mutations in TBP^s- Also examined were the Oct-2^ and 
Spl^ activators, which yielded results similar to those of 
Oct-2*-* (data not shown). The combination of all four 
HI', H2, S3/S4, and S3'/S4' mutations in TEP^s (lane 
13, A-D) disrupted the ability of TBP to respond to any of 
the activation domains examined. Analysis of the double 
(lanes 3-8) and triple (lanes 9-12) combined sets of mu­
tants, however, revealed that the activity of TBP in vivo 
is sensitive only to specific combinations of these mu­
tations. 
Certain combined sets of mutations produced consis­
tent effects on activated transcription, regardless of the 
WT 
n r 
double 
nr 
triple quad. 
II—I 
GST-hTBPAs: 
EXTRACT: 
- 1^  ^ ^# 5 
+ + + + + 
c-fos 
1 2 3 4 5 6 
Figure 5. Alanine substitution mutations on the surface of hu­
man TBP affect basal transcription in vitro. Results of RNase 
protection analysis performed on RNA transcribed in crude 
HeLa nuclear extract in vitro, supplemented with recombinant 
GST-hTBPAS/ are shown. Each reaction contained 32 ixg of 
crude HeLa cell nuclear extract, 160 ng of c-/os (TGTAAA) re­
porter, and 15 ng of full-length GST-hTBPAS/ wild-type or mu­
tant as indicated (lanes 2-6). The position of correctly initiated 
transcripts from the c-/os reporter is shown. An asterisk (*) in­
dicates an RNase-resistant signal that results from hybridiza­
tion of the RNA probe with the c-/os reporter DNA. 
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Figure 6. Combined mutations in different regions of TBP at­
tenuate transcriptional response in vivo. RNase protection anal­
ysis was performed on RNA isolated from transiently trans-
f ected HeLa cells, as described in Materials and methods and the 
legend to Fig. 3. Only correctly initiated transcripts from the 
c-/os reporter are shown; different exposures of each autoradio-
graph are presented for each activator, (double, triple, and quad.) 
The number of sets of clustered alanine mutations in each hu­
man TBP (see Table 1), not the total number of point mutations; 
(WT) wild-type TBP^s (lane 2). [Top] { + ] The presence of the 
particular double or triple alanine substitution mutation de­
scribed in Table 1; (-) wild-type TBP sequence at that position. 
identity of the activation domain. Any double combina­
tion of the HI', S3/S4, and S3'IS4' mutations (lanes 
4,5,8) had little if any effect on the response to each 
activator, except for V P 1 6 N which was reduced threefold 
by the S3/S4 + S3'/S4' combination (cf. lanes 2 and 8, D). 
In contrast, combining the H2 mutation with any of the 
other mutations (lanes 3,6,7) disrupted response to all of 
the activators, especially VP16 (lanes 3,6,7, C). For the 
other activators, the H2 + S3'/S4' combination was the 
most severe of any of the double combinations (lane 7, 
A,B,D). The sensitivity of TBP to combined sets of mu­
tations across different regions of the protein, but not to 
individual mutations, suggests that multiple surfaces of 
TBP participate in response to RNA polymerase II trans-
activators in vivo. Moreover, because TBP can appar­
ently tolerate loss of function in isolated regions of the 
protein, the individual participation of each surface of 
TBP is not obligatory for transcriptional activity. 
In contrast to these universal effects on TBP^s re­
sponse to activators, certain combined mutations pre­
dominantly affected activation by the VP16 activation 
domain, hi particular, the HI'+ S3/S4 + S3'/S4' triple 
combination supported wild-type levels of activation by 
CTF^ but was <10% active for response to VP16 (Fig. 6, 
lane 11, cf. B and C). Curiously, unlike the response to 
single sets of mutations (see Fig. 3), the response of each 
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of the combined sets of mutations to VP16N more 
closely mirrored the response to Oct-2^ and CTF^ than 
to full-length VP16. This comparison raises the possibil­
ity that the VP16-specific defect of the Hl' + S3/S4 + 
S3'/S4' mutant TBP^s is a result of the high activity of 
the full-length VP16 activation domain. The activation 
domain-specific defect of this mutant TBP makes two 
important points: (1) It shows that, although the HI' + 
S3/S4 + S3'/S4' mutant TBP is only weakly active for 
VP16, this loss of activity is not the result of a general­
ized disruption of the integrity or accessibility of the 
TBP, because it functions at wild-type levels for CTF^, 
and (2) it demonstrates that activators can differ in how 
they directly or indirectly utilize different residues in 
TBP to activate transcription. 
Interaction of TBP with hTAPii250 is resistant 
to mutations in single regions of TBP but is disrupted 
by specific combinations of mutations 
The ability of different mutant TBPs to support activated 
transcription in vivo did not correlate with their ability 
to interact with DNA or to support basal transcription in 
vitro. To probe the mechanisms that dictate TBP activity 
in vivo, we investigated the effect of our alanine substi­
tution mutations on the interaction of TBP with two 
other components of the transcriptional apparatus. Be­
cause TBP only supports activated transcription in vitro 
when assembled into a partial or complete TFIID com­
plex (Dynlacht et al. 1991; Tanese et al. 1991; Zhou et al. 
1993; Chen et al. 1994), we examined mutant TBP asso­
ciation with hTAFn250 in vitro. Human TAFn250 binds 
directly to TBP and appears to form a scaffold for the 
assembly of TFIID (Goodrich et al. 1993; Ruppert et al. 
1993; Weinzierl et al. 1993; Verrijzer et al. 1994; Chen et 
al. 1994); thus, the ability of TBP to interact with 
hTAFii250 is probably a good measure of its ability to be 
recruited into TFIID. Additionally, hTAFn250 has been 
shown to be crucial for transcriptional activation in vivo 
(Wang and Tjian 1994). However, although the carboxy-
terminal core of TBP is sufficient for the assembly of an 
active TFIID complex (Zhou et al. 1993), little is known 
about the residues in the core of TBP that are required for 
association of TBP with hTAFii250. In addition, we also 
examined interaction of these mutant TBP molecules 
with TFIIB in vitro, as TFIIB is known to interact with 
both TBP and activator proteins in vitro (Lin et al. 1991; 
Ha et al. 1993) and has been implicated as an important 
functional target for transcriptional activators (Lin and 
Green 1991). 
In vitro-translated radiolabeled wild-type and mutant 
TBPAS molecules were mixed with hemagglutinin influ­
enza virus (HA) epitope-tagged hTAFn250 or GST-TFIIB 
and either coimmunoprecipitated with antibodies 
against the HA-epitope tag (hTAFu250) or cobound to 
glutathione beads (TFIIB). After extensive washing, the 
labeled TBP that remained bound to the precipitated 
hTAFn250 or TFIIB was analyzed by SDS-PAGE followed 
by autoradiography. The presence of the altered-specific-
ity substitutions did not affect the ability of wild-type 
TBP to interact with either hTAFn250 or human TFIIB in 
vitro (data not shown). Figure 7 shows the results of 
these experiments. Figure 7A shows 10% of the input 
TBP for each assay. As a negative control for the TBP-
hTAFii250 interaction, we also examined the interaction 
of labeled mutant TBPAS molecules with beads carrying 
just the anti-HA antibody: Binding of labeled TBP^^ s to 
these control beads (Fig. 7D) was ~ 1 % that of binding to 
beads containing hTAFii250. In a siinilar control exper­
iment for the interaction of TBP with GST-TFIIB, we 
found that ~ 10-fold more TBP^s bound to GST-TFIIB 
beads than to GST-alone beads (data not shown). 
None of the mutations, including the quadruple com­
bination mutation HI'+ H2 + S3/S4 + S3'/S4' (lane 16), 
had a large effect on the interaction of TBP with human 
TFIIB (cf. Fig. 7, A and C). This result suggests that these 
mutations do not target the residues of TBP that interact 
with TFIIB under these conditions and is consistent with 
the finding that large regions of TBP can be deleted with­
out disrupting the TBP-TFIIB interaction in this type of 
assay (Ha et al. 1993). 
In contrast, the ability of these TBP molecules to in­
teract with hTAFn250 was strongly affected by some of 
the mutations (cf. Fig. 7, A and B). As with in vivo tran­
scriptional activity, the interaction of hTAFii250 with 
TBP was largely resistant to the effects of mutations in 
single regions of TBP. The only single regional mutation 
that had a detectable effect was the H2 mutation, which 
reduced twofold the ability of TBP^s to interact with 
hTAFn250 (Fig. 7B, cf. lanes 1 and 3). When different 
mutations on the surface of TBP were combined, inter­
action between TBP and hTAFn250 could be strongly 
affected. In particular, any combinations of the H2 and 
S3'/S4' mutations (lanes 10,13,15,16) reduced the ability 
of TBP to interact with hTAFii250 to 10% or less of 
wild-type levels. These data suggest that TBP interacts 
with hTAFii250 by making multiple contacts across its 
surface and that any one point of interaction between 
TBP and hTAFii250 can be disrupted without disrupting 
the overall integrity of the TBP-hTAFn250 association. 
In Figure 7E, the interaction of the various mutant 
TBP molecules with hTAFn250 is summarized and com­
pared with the results of CTF^ and VP16 activation in 
vivo. Generally, the ability of wild-type and mutant TBP 
molecules to respond to transcriptional activators in 
vivo closely paralleled their ability to interact with 
hTAFji250 in vitro. In particular, all mutations in TBP 
that reduced interaction with hTAFii250 in vitro by 10-
fold (columns 10,13,15,16, E; those that carry the 
H2 + S3'/S4' combination) were defective for transcrip­
tional activation in vivo. Similarly, the mutant TBP mol­
ecules carrying double or triple combinations of the HI', 
S3/S4, and S3'/S4' mutations (columns 7,8,11,14) retain 
considerable in vivo activity for response to CTF^ and 
associate better with hTAFii250 than the less active mu­
tants. The VP16-derived activator, however, did not ac­
tivate transcription at full potential even when TBP 
could associate effectively with hTAFii250, albeit at a 
lower level, as in the case of the HI'+ S3/S4 + S3'/S4' 
triple mutant (column 14). This result suggests that to 
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triple quad. 
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Figure 7, Combined mutations in different regions of TBP disrupt interaction with hTAFulSO in vitro. [A-D] Coimmunoprecipita-
tion and GST-pulldown assays. ^^S-Labeled, in vitro-translated human TBPAS molecules, as indicated, were incubated with either 
HA-tagged, baculovirus-expressed hTAFnlSO [B], or £. coii-expressed GST-linked human TFIIB (C). The interaction of these mutant 
TBPs with hTAFii250 was measured by their ability to be coimmunoprecipitated with antibodies against the HA epitope tag; inter­
action with TFIIB was measured by their ability to be precipitated by coupling of GST-TFIIB to glutathione-agarose. Also shown are 
10% of the labeled input TBP [A] and background binding to the aHA beads (D). (£) Interaction of mutant TBPs with hTAFnlSO 
compared with in vivo response to VP16 and CTF^. hTAFnlSO interaction with wild-type TBP AS was set to 1.0 and was calculated as 
follows: ^^S-Labeled TBP bands from the gels shown in B were quantitated by Phosphorlmaging, and each value was corrected for 
background binding to the aHA beads alone and for minor differences in input protein. In vivo activity was calculated by quantitation 
of the gels shown in Figs. 3 and 6 by Phosphorlmaging, subtraction of the activity observed in the presence of activator but in the 
absence of TBP^s, and setting the rescued level of transcription by wild-type TBP^s for each activator to 1.0. 
reach its full activation potential, VP16 requires more 
than simply the ability of TBP to associate with 
hTAFn250. 
Given the marked differences in the assays used to 
measure TBP activity in vivo and its interaction with 
hTAFn250 in vitro, the qualitative similarities in the 
activation and hTAFii250-association profiles are strik­
ing. These data suggest that the resilient nature of the 
interaction of TBP with hTAFnlSO is the reason why 
TBP activity in vivo is resistant to single sets of amino 
acid substitutions. They also suggest that interaction of 
TBP with hTAFn250 plays a central role in the response 
of TBP to a diverse range of transcriptional activation 
domains. 
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Discussion 
TBP performs a range of diverse activities within the 
cell. It is involved in transcription by all three nuclear 
RNA polymerases, from promoters with or without a 
TATA box. TBP achieves much of this diversity by in­
teracting with different sets of TAFs, depending on the 
polymerase and promoter context (see Hernandez 1993; 
Goodrich and Tjian 1994). These many different physical 
associations probably place large constraints on the 
structure of TBP, which may explain why the carboxy-
terminal core of the protein has been so highly conserved 
throughout evolution. 
We have studied the surfaces of TBP that are required 
in vivo for just one of its many functions: activated RNA 
polymerase II transcription from a TATA box-containing 
promoter. The highly conserved TBP core is sufficient to 
respond to a battery of different activation domains in 
human cells, but, to our surprise, the high degree of se­
quence conservation in this region of the molecule is not 
required (Fig. 3). Indeed, TBP can withstand multiple 
amino acid substitutions within individual regions of 
the conserved domain without losing the ability to re­
spond to the activators tested in our transient expression 
assay. This result suggests that it is likely to be other 
aspects of TBP function that constrain its evolutionary 
sequence divergence. 
One possible constraint is the role played by TBP in 
RNA polymerase III transcription. When single amino 
acid substitutions within the top surface of TBP (as rep­
resented in Fig. lA) that affect yeast cell viability have 
been identified, they predominantly affect RNA poly­
merase III transcription (Cormack and Struhl 1993; Cor-
mack et al. 1994). This result could simply mean that the 
top surface of TBP has little involvement in transcrip­
tion by RNA polymerase 11. Alternatively, the activity of 
yeast TBP in RNA polymerase II transcription may also 
be resistant to single amino acid substitutions; perhaps 
combinations of amino acid substitutions in yeast TBP, 
as in human TBP, would affect its activity in RNA poly­
merase II transcription. 
Transcription by RNA polymerase II differs signifi­
cantly from that by the other RNA polymerases, because 
RNA polymerase II must respond to many different se­
quence-specific transcription factors. The coactivator 
hypothesis (Pugh and Tjian 1992) posits that complexed 
with TBP are proteins—coactivators—that serve as in­
termediaries between activators and RNA polymerase II. 
Indeed, TAFs display coactivator activity (Dynlacht et al. 
1991; Tanese et al. 1991; Chen et al. 1994). Coactivators 
thus permit the activity of diverse sequence-specific ac­
tivators to be directed toward activation of a single RNA 
polymerase. By virtue of its ability to bind to both the 
TATA box and TAFs, TBP targets coactivators to TATA 
box-containing promoters. The correlation described 
here between TBP-TAF interaction in vitro and the re­
sponse of TBP to many different activation domains in 
vivo (Fig. 7E) is consistent with this hypothesis. 
The ability of yeast TBP to respond to a variety of 
transcriptional activation domains in human cells (Fig. 
3) suggests that, during evolution, the interface between 
TBP and other components of the transcriptional ma­
chinery has been conserved. This conserved interface 
could well be that between TBP and the TAFs. Like hu­
man cells, yeast contain TAFs (Poon and Weil 1993), 
including a direct structural homolog of the human TBP-
binding TAFH250 (A. Weil, pers. comm.). Furthermore, 
yeast TBP can bind hTAFnlSO in vitro (S. Ruppert and R. 
Tjian, unpubl.). Thus, this TBP-TAF interaction, which 
is involved in recruiting TBP into the TFIID complex, 
has been evolutionarily conserved, perhaps reflecting its 
universal importance to activated RNA polymerase II 
transcription in vivo. 
Although the activation domains of Spl (Kiinzler et al. 
1994) and Oct-l^ (C. Hinkley and W. Herr, unpubl.) do 
not function in yeast, they can activate transcription 
with yeast TBP in human cells (Fig. 3). This finding sug­
gests that one or more elements other than the interface 
between TBP and the transcriptional machinery have 
diverged between yeast and humans. One possibility 
is that the full complement of TFIID TAFs has not 
been universally conserved. For example, Drosophila 
TAFijllO responds to a glutamine-rich activation do­
main from Spl (Hoey et al. 1993; Chen et al. 1994): 
Perhaps in yeast either this TAF is absent or a homolog 
has lost the ability to respond to the Spl activation do­
main. Such changes in TAFs could result in changes in 
transcriptional response to entire classes of activation 
domains during speciation or even during cell differen­
tiation if TAF expression is developmentally controlled. 
To contrast the activity of TBP point mutants in vivo 
with their in vitro activities, we assayed the effects 
of clustered alanine substitution mutations in four in 
vitro assays: (1) basal transcription, (2) binding to DNA, 
(3) association with TFIIB, and (4) association with 
hTAFn250. Only the association with hTAFii250 corre­
lated with in vivo activity (Fig. 7). TFIIB association was 
unaffected by any of the mutations (Fig. 7), whereas both 
DNA binding and basal transcription in vitro (Figs. 4 and 
5) were disrupted by individual sets of point mutations 
that had little if any effect in vivo. It is known that 
defects in DNA binding by yeast TBP can be overcome in 
vivo and during in vitro basal transcription (Cormack 
and Struhl 1992; Lee et al. 1992; Schultz et al. 1992; 
Yamamoto et al. 1992). 
We were surprised, however, that human TBP mutants 
that supported activated transcription in vivo could be 
defective for basal transcription in vitro. We imagined 
that the ability to support basal transcription would be a 
likely prerequisite for TBP to respond to activators. As 
suggested above, perhaps the interactions of TBP in vivo 
with cellular components can counteract the effects of 
these TBP mutations. A good candidate for such an in­
teraction is that between TBP and TAFs in TFIID and, in 
particular, between TBP and hTAFii250, which recruits 
TBP into TFIID (Ruppert et al. 1993; Weinzierl et al. 
1993; Chen et al. 1994). 
The association of hTAFn250 with TBP in vitro ap­
pears to involve interactions with multiple surfaces of 
TBP and is resistant to changes in isolated regions of TBP 
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(Fig. 7). These effects correlate with the in vivo activity 
of TBP and suggest an extensive and stable interaction 
between TBP and T A F H 2 5 0 . Although we do not dis­
count the possibility that the effects of these mutations 
on hTAFii250 interaction could be indirect, such an ex­
tensive interaction is consistent with the stable associ­
ation of TBP with TAFs in the TFIID complex (Dynlacht 
et al. 1991; Tanese et al. 1991; Zhou et al. 1993). It is also 
consistent with the observation that multiple regions of 
hTAFnlSO can independently interact with TBP in vitro 
(S. Ruppert and R. Tjian, xmpubl.). But why does TBP rely 
on an extensive interaction with hTAFn250 across its 
surface in this way? 
We propose that by utilizing multiple points of contact 
across its surface, TBP is able to interact with hTAFn250 
and, in turn, a network of other TAFs in a way that is 
both strong and flexible. This may have several conse­
quences for the functioning of TBP in vivo. First, the 
resilience of the interaction of TBP with hTAFii250 
raises the possibility that once TBP enters TFIID, it may 
not be available for interaction with the other TBP-con-
taining complexes (such as SLl and TFIIIB; for review, 
see Goodrich and Tjian 1994). As TBP is apparently lim­
iting for RNA polymerase II and III transcription (Cor-
mack and Struhl 1993), the distribution of TBP into the 
various TAF-containing complexes may have important 
consequences for coordinating transcription within the 
cell. Second, as there are multiple points of contact be­
tween TBP and hTAFQ250, it is possible that one or 
more of these individual interactions could be disrupted 
without destroying the overall integrity of the TBP-
hTAFn250 association. In this way, the precise nature of 
the TBP-hTAFii250 association could change, perhaps 
allowing TBP to also make direct contact with activators 
or with other GTFs. 
In addition to the importance of the TBP-TAFn250 
interaction for activated transcription we observe with 
all activators tested, there are elements of TBP function 
that selectively affect the activity of one but not other 
activation domains. This property is exemplified by the 
sensitivity of the VP16 activation domain to mutations 
that do not affect the activity of other activation do­
mains, in particular, the multiple regional point mutant 
Hl' + S3/S4 + S3'/S4', which severely disrupts activa­
tion by VP16 but not CTF^ (Fig. 6). The behavior of this 
mutant TBP demonstrates that TBP itself, a single com­
ponent of the basal transcriptional machinery, can be 
used in different ways to achieve transcriptional activa­
tion. 
The differential effects of the HI'+ S3/S4 + S3'/S4' 
mutant may reflect the unusual potency of VP16. Al­
though this combined mutation in TBP reduced VP16 
activation by > 10-fold, the absolute level of activation 
achieved by VP16 in this instance is very similar to that 
seen with CTF^ (Fig. 2A). One possible mechanism for 
such an unusual potency is that VP16 has a greater range 
of targets in the transcriptional apparatus. This mecha­
nism is implied by the biochemical characterization of 
multiple potential targets for VP16, which thus far in­
clude TFIIB (Lin and Green 1991; Lin et al. 1991), TBP 
(Ingles et al. 1991), and TAFn40 (Goodrich et al. 1993). It 
is also consistent with the observation that V P 1 6 N was 
affected less severely by the H1' + S3'S4 + 
S3'/S4' mutation than the more active full-length acti­
vation domain (see Fig. 6). VP16 may thus achieve 
greater levels of activation by stimulating additional or 
different targets than CTF^: The HI'+ S3/S4 + S3'/S4' 
mutation may disrupt the interaction of TBP with these 
VP16-specific targets, either directly or by inducing 
changes in the hTAFii250-TBP complex that in some 
way weaken recognition by critical VPI6 coactivators, 
such as a human homolog of the Diosophila TAFu40 
(Goodrich et al. 1993). 
In conclusion, our in vivo and in vitro studies of TBP 
function suggest that TBP responds to activators by more 
than one pathway: one broadly used pathway involving 
association with TFIID through an extensive interaction 
with TAFn250 and a second pathway that may only be 
used by a selected set of activation domains, including 
the very potent VP16 activation domain. 
Materials and methods 
Constiuction of mutant TBP molecules and GAL4-activatois 
TBP-encoding sequences were subcloned into the mammalian 
expression vector pCGN (Tanaka and Herr 1990), which adds a 
15-amino-acid HA epitope tag to the amino terminus of the 
expressed protein. To minimize translation initiation after the 
epitope tag, the full-length wild-type and altered-specificity hu­
man TBP pCGN clones [gifts from M. Tanaka and R. Mital, 
respectively (Cold Spring Harbor Laboratory)] were modified by 
site-directed in vitro mutagenesis (Kunkel et al. 1987) to remove 
sequences encoding the initiator methionine of human TBP. 
Yeast TBP sequences (encoding amino acids 2-240 of S. ceievi-
siae TBP) were amplified from genomic DNA (gift of K. Gavin, 
Cold Spring Harbor Laboratory) by the polymerase chain reac­
tion (PCR) with 5' Mi el- and 3' BamHI-adapter primers. After 
restriction enzyme digestion, the resulting fragment was sub-
cloned into the unique Xbal and BamHl sites of pCGN and 
site-directed mutagenesis was used to introduce (1) the triple 
amino acid altered-specificity substitution (Strubin and Struhl 
1992) and (2) two silent mutations at codons 61 and 62, which 
removed a cryptic splice-site donor that prevented expression of 
full-length yeast TBP in HeLa cells (W.P. Tansey and W. Herr, 
unpubl.). Single regional point mutations in human and yeast 
TBP {HI, HI', H2, H2', S3/S4, S3'/S4', IIA, and poi III] were 
generated by site-directed mutagenesis with single synthetic 
oligonucleotides carrying the desired mutations; multiple re­
gional point mutants were generated with a pool of the HI', H2, 
S3/S4, and S3'/S4' mutagenic oligonucleotides. 
To prepare the pT^-TBP^s constructs for in vitro translation, 
inserts of the pCGNTBP^s constructs were amplified by PCR 
with 5' Ndel- and 3' BamHl-adapter primers. The products were 
digested with Ndel and BamHl and subcloned into pTpSTOP 
(gift of H. Jantzeu; Jantzen et al. 1992) to yield the corresponding 
pT^TBP^s constructs used for in vitro transcription/transla­
tion. The sequence integrity of all constructs was confirmed by 
dideoxy sequence analysis of the entire conserved region of TBP. 
GAL4-fusion activators were constructed by subcloning var­
ious activator-derived sequences into the vector pCG—GAL(1-
94) (Tanaka et al. 1994; modified by C. Hinkley—to be de­
scribed elsewhere). The GAL4—CTF^ fusion was produced by 
PCR amplification of CTF sequences (encoding amino acids 
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399-499 of CTF; Mermod et al. 1989) from pSG + CTF (gift of N. 
Mermod; Martinez et al. 1991) with 5' Xbal and 3' BamHl 
adapter primers and ligating the cleaved fragment into the 
unique Xbal and BamHI sites of pCG-GAL(l-94). Spl se­
quences (encoding amino acids 263-391 of Spl; Courey and 
Tjian 1988) were PCR-amplified from pSG + SplN [gift of G. 
Gill (University of California, Berkeley); Li et al. 1991] with 5' 
Bbsl- and 3' BamHI-adapter primers, cleaved, and ligated in 
tandem into the unique Bbsl and BamHl sites of pCG-GAL(l-
94). This manipulation produced an in-frame fusion of the 
GAL4 DNA-binding domain with two copies of the Spl B do­
main, adding the sequence EDEPQSS between the two Spl re­
peats. The VP16N (413-456) and VP16c (452-490) GAL4-fusion 
constructs were produced by loop-out site-directed mutagenesis 
of the parental pCG-GAL( l-94)VP16(413-490) construct [gift of 
G. Das (Cold Spring Harbor Laboratory)]. 
Alteied-specificity TBP assay 
HeLa cells were transiently transfected by the calcium phos­
phate coprecipitation method as described (Tanaka et al. 1992). 
Each transfection included (1) 200 ng of c-/os (-56)[4xGAL] 
reporter, either wild-type (gift of M. Tanaka; Tanaka et al. 1994) 
or carrying the TAT AAA to TGTAAA mutation (introduced by 
site-directed mutagenesis); (2) between 160 ng and 1.76 |xg of 
pCGNTBP expression plasmid (adjusted to give equivalent lev­
els of expression for each HA-tagged TBP); (3) between 350 and 
720 ng of pCG-GAL4-activator expression plasmid (the amount 
for each determined empirically to give maximal activation of 
the wild-type c-/os reporter); (4) 80 ng of a-globin internal ref­
erence plasmid pa4x(A + C) (Tanaka et al. 1988); and (5) 
pUC119, taking the total amount of transfected DNA to 20 |xg. 
At 36 hr post-transfection, cells were harvested and cytoplasmic 
RNA prepared as described (Tanaka et al. 1992). RNase protec­
tion analysis (Tanaka et al. 1992) was used to quantitate cor­
rectly initiated transcripts from the c-/os reporter and from the 
a4x( A + C) internal control plasmid. TBP expression levels were 
determined by transfecting threefold titrations of each expres­
sion construct, followed by Western blot analysis of protein 
extracts from transfected cells with an antibody probe (12CA5) 
against the HA epitope tag. 
Pioduction of recombinant proteins 
Altered-specificity TBP sequences were subcloned into the 
unique Xbal and BamHl sites of pETllcGST (Lai et al. 1992) 
and expressed in E. coli as GST fusion proteins by use of the T7 
expression system developed by Studier et al. (1990). E. coli 
BL21(DE3) cultures of 500 ml carrying the appropriate 
pETllcGST-TBP^s construct were grown at 30°C to an OD595 
of 0.6. At this point, IPTG was added (0.5 mM final concentra­
tion) and the cultures induced were for 4 hr at 30°C; growth and 
induction at this temperature resulted in the highest yield of 
soluble induced protein. After induction, cells were harvested 
by centrifugation, resuspended in 30 ml of lysis buffer [25 mM 
HEPES-KOH (pH 7.9 at 4°C), 20% glycerol, 12.5 mM MgCli, 2 
mM EDTA, 2 mM DTT, 0.2 mM PMSF, 5 M-g/ml of aprotinin, 5 
fx,g/ml of leupeptin, and 5 |xg/ml of pepstatin], and lysed by 
treatment with lysozyme (final concentration of 100 |xg/ml) and 
the addition of NP-40 to 0.1% (final concentration). The lysate 
was then sonicated to shear bacterial DNA, and insoluble pro­
teins were removed by centrifugation. GST-fusion proteins 
were purified from the soluble fraction by binding to 200 |xl of 
glutathione-agarose (Sigma) for 1 hr at 4°C, washing extensively 
with HEMGN buffer (Lieberman and Berk 1991) containing 0.15 
M KCl, and eluting with two lots of 100 |xl of 5 mM reduced 
glutathione (in HEMGN with 0.15 M KCl). Samples of the elu-
ates were analyzed by SDS-PAGE combined with Coomassie 
staining and Western blot analysis. Typically, a 500-ml culture 
yielded between 5 and 20 |xg of full-length GST-TBPAS, in a 
form that was essentially free of non-TBP-related proteins; 
these preparations did, however, contain a significant propor­
tion of inactive carboxy-terminal TBP breakdown products. 
DNA-binding and basal transcription analyses 
DNase 1 footprinting analysis was performed with purified re­
combinant GST-TBPAS fusion proteins. The c-/os TGTAAA 
probe was prepared by PCR from the c-/os (-56)[4xGAL] 
TGTAAA reporter with an vmlabeled reverse sequencing primer 
and an end-labeled primer that hybridized to c-/os promoter 
sequences sparming -I- 6 to -I- 23. Each binding reaction included 
10,000 cpm of probe, 15-150 ng of full-length GST-TBP^s, 50 
ng of poly[d(G-C)], 2% polyvinyl alcohol, 2 |xg of BSA, 12.5 mM 
HEPES-KOH (pH 7.9], 75 mMKCl, 0.1 mM EDTA, 10% glycerol, 
5 mM MgClj, 1 mM DTT, 0.1 mM PMSF, and 0.05% NP-40, in a 
total volume of 25 |xl and was allowed to proceed for 40 min at 
30°C. DNase I digestion was then carried out as described 
(Schmidt et al. 1989), and reaction products were analyzed by 
denaturing poly aery lamide gel electrophoresis. G-l-A chemical 
sequencing reactions of the c-/os TGTAAA probe were run 
alongside the footprinting reactions. 
In vitro transcription from the c-/os {- 56)TGTAAA template 
was performed in crude HeLa cell nuclear extract (Dignam et al. 
1983) supplemented with purified recombinant GST-TBPAS-
Reactions contained 4 |JL1 of nuclear extract (32 [jig of total pro­
tein), 160 ng of c-/os ( - 56)[4xGAL]TGTAAA reporter plasmid, 
15 ng of the appropriate full-length GST-TEP^s fusion protein, 
20 mM HEPES-KOH (pH 7.9), 62.5 mM KCl, 5 mM ammonium 
sulfate, 3% polyethylene glycol 8000, 8 mM MgClj, 10% glyc­
erol, 1 mM DTT, and 0.7 mM each of ATP, CTP, UTP, and GTP. 
After a 60-min incubation at 30°C, the reaction mixture was 
treated with proteinase K and SDS and extracted with phenol/ 
chloroform, and nucleic acids were precipitated with ethanol. 
RNA transcribed in vitro was then analyzed by RNase protec­
tion analysis (Tanaka et al. 1994). 
Coimmunoprecipitations and GST puUdowns 
HA epitope-tagged hTAFii250 was expressed in baculovirus-in-
fected SF9 cells and whole-cell extracts were prepared as de­
scribed (Ruppert et al. 1993). After diluting the extract to 
HEMGN containing 0.3 M KCl (0.3 HEMGN) and clearing it by 
centrifugation, the supernatant was incubated for 4 hr on ice 
with anti-HA (12CA5) antibodies (BAbCO). The extract was 
cleared again by centrifugation, and the 12CA5 antibody and 
immunopurified hTAFii250 was precipitated from the superna­
tant by binding to protein A-Sepharose CL-4B beads (Pharma­
cia). The beads were washed extensively with 0.1 HEMGN and 
analyzed by SDS-PAGE and Coomassie staining. ^^S-Labeled 
TBPAS proteins were generated from the pTp-TBP^s constructs 
by in vitro transcription/translation using the T N T coupled re­
ticulocyte lysate system (Promega). The in vitro-translated pro­
teins were diluted with four volumes of 0.1 HEMGN and 
cleared by centrifugation. Fifty microliters of the supernatant 
was incubated with 25 [xl of packed protein A beads containing 
either 12CA5 and -200-300 ng of full-length hTAFii250 or 
12CA5 alone. After nutating 3-4 hr at 4°C, bound TBP^s pro­
teins were recovered by low speed centrifugation and the beads 
were washed extensively with 0.1 HEMGN. The bovmd pro­
teins, 10% of the input TEP^s, and an aliquot of the final wash 
were analyzed by SDS-PAGE, followed by silver-staining and 
GENES & DEVELOPMENT 2767 
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
Tansey et al. 
autoradiography. Bound TBPAS proteins were quantitated by 
Phosphorlmaging and corrected for background binding to aHA 
|12CA5) beads and for minor variations in protein input. 
GST-TFIIB and control GST proteins were expressed from 
the T7 expression vectors (gift of D. Reinberg; Ha et al. 1993) in 
E. coli DH5a, purified by binding to glutathione-Sepharose 4B 
beads (Pharmacia), and analyzed by SDS-PAGE and Coomassie 
staining. Beads containing 200-300 ng of GST-TFIIB fusion pro­
tein or 500 ng of GST alone were incubated with ^^S-labeled 
TBPAS and analyzed as described above. Approximately 10-fold 
more TfiP^s proteins were bound to the GST-hTFIIB beads than 
to the control GST beads. 
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